Johnson & Johnson (NYSE:JNJ) Trading 0.3% Higher

Johnson & Johnson (NYSE:JNJ) shares traded up 0.3% on Friday . The stock traded as high as $146.77 and last traded at $146.27. 1,234,257 shares traded hands during trading, a decline of 83% from the average session volume of 7,344,341 shares. The stock had previously closed at $145.80.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. The Goldman Sachs Group assumed coverage on Johnson & Johnson in a research note on Thursday, May 30th. They set a “neutral” rating and a $160.00 target price for the company. HSBC raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and increased their target price for the company from $169.00 to $170.00 in a research report on Thursday, April 18th. Morgan Stanley decreased their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 17th. Royal Bank of Canada reissued an “outperform” rating and set a $175.00 target price on shares of Johnson & Johnson in a research report on Monday, June 17th. Finally, Bank of America decreased their target price on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. Eight analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $174.07.

Johnson & Johnson Trading Up 0.2 %

The business has a fifty day moving average of $148.14 and a 200-day moving average of $154.06. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.94 and a current ratio of 1.17. The company has a market capitalization of $351.76 billion, a P/E ratio of 9.11, a PEG ratio of 2.43 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The company had revenue of $21.38 billion for the quarter, compared to analysts’ expectations of $21.39 billion. During the same period last year, the business earned $2.68 EPS. Johnson & Johnson’s quarterly revenue was up 2.3% compared to the same quarter last year. Analysts anticipate that Johnson & Johnson will post 10.62 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st were paid a dividend of $1.24 per share. The ex-dividend date of this dividend was Monday, May 20th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 annualized dividend and a yield of 3.39%. Johnson & Johnson’s dividend payout ratio (DPR) is 30.92%.

Hedge Funds Weigh In On Johnson & Johnson

Large investors have recently bought and sold shares of the stock. Christopher J. Hasenberg Inc bought a new position in Johnson & Johnson during the 1st quarter valued at $31,000. Keener Financial Planning LLC purchased a new stake in shares of Johnson & Johnson during the 4th quarter valued at $40,000. WFA Asset Management Corp raised its stake in shares of Johnson & Johnson by 61.4% during the 4th quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock worth $40,000 after purchasing an additional 97 shares during the period. Vermillion & White Wealth Management Group LLC bought a new position in Johnson & Johnson during the fourth quarter valued at about $44,000. Finally, Disciplined Equity Management Inc. purchased a new stake in Johnson & Johnson during the fourth quarter worth about $45,000. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.